[go: up one dir, main page]

WO2015051268A3 - Hiv protease inhibitors against picornavirus infection - Google Patents

Hiv protease inhibitors against picornavirus infection Download PDF

Info

Publication number
WO2015051268A3
WO2015051268A3 PCT/US2014/059089 US2014059089W WO2015051268A3 WO 2015051268 A3 WO2015051268 A3 WO 2015051268A3 US 2014059089 W US2014059089 W US 2014059089W WO 2015051268 A3 WO2015051268 A3 WO 2015051268A3
Authority
WO
WIPO (PCT)
Prior art keywords
protease inhibitors
hiv protease
inhibitors against
picornavirus infection
against picornavirus
Prior art date
Application number
PCT/US2014/059089
Other languages
French (fr)
Other versions
WO2015051268A2 (en
Inventor
Xiao-Fang Yu
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of WO2015051268A2 publication Critical patent/WO2015051268A2/en
Publication of WO2015051268A3 publication Critical patent/WO2015051268A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to methods for treating viral infections. In particular, the present invention is directed to methods for treating picornavirus infection using HIV protease inhibitors.
PCT/US2014/059089 2013-10-04 2014-10-03 Hiv protease inhibitors against picornavirus infection WO2015051268A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361886765P 2013-10-04 2013-10-04
US61/886,765 2013-10-04
US201461940755P 2014-02-17 2014-02-17
US61/940,755 2014-02-17

Publications (2)

Publication Number Publication Date
WO2015051268A2 WO2015051268A2 (en) 2015-04-09
WO2015051268A3 true WO2015051268A3 (en) 2015-06-04

Family

ID=52779301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/059089 WO2015051268A2 (en) 2013-10-04 2014-10-03 Hiv protease inhibitors against picornavirus infection

Country Status (1)

Country Link
WO (1) WO2015051268A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108424881B (en) * 2018-03-23 2021-07-27 中国食品药品检定研究院 A strain of enterovirus 68 and its application in preparing EV-D68-infected animals
CN115697328A (en) * 2020-03-23 2023-02-03 约翰·M.H.·格雷格 Antiviral compounds and methods of administration thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110263620A1 (en) * 2010-04-23 2011-10-27 National Health Research Institutes Quinoline compounds and their use for treating viral infection
WO2013112780A1 (en) * 2012-01-26 2013-08-01 Life Technologies Corporation Methods for increasing the infectivity of viruses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110263620A1 (en) * 2010-04-23 2011-10-27 National Health Research Institutes Quinoline compounds and their use for treating viral infection
WO2013112780A1 (en) * 2012-01-26 2013-08-01 Life Technologies Corporation Methods for increasing the infectivity of viruses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DICENZO ET AL.: "Pharmacokinetics of Indinavir and Nelfinavir in Treatment-Naive, Human Immunodeficiency Virus-Infected Subjects", ANTIMICROB. AGENTS CHEMOTHER., vol. 48, no. 3, March 2004 (2004-03-01), pages 918 - 923, Retrieved from the Internet <URL:http://aac.asm.org/content/48/3/918.short> [retrieved on 20150309] *
PATICK ET AL.: "Protease Inhibitors as Antiviral Agents", CLINICAL MICROBIOLOGY REVIEWS, October 1998 (1998-10-01), pages 614 - 627, XP001145676 *
PEVEAR ET AL.: "Relationship of Pleconaril Susceptibility and Clinical Outcomes in Treatment of Common Colds Caused by Rhinoviruses", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, November 2005 (2005-11-01), pages 4492 - 4499 *

Also Published As

Publication number Publication date
WO2015051268A2 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
MX2019003525A (en) Hepatitis b core protein allosteric modulators.
CO2017002170A2 (en) Combination therapy to treat a paramyxovirus
MX373703B (en) AZEPANO DERIVATIVES AND METHODS FOR TREATING HEPATITIS B INFECTIONS.
PH12017500207A1 (en) Indoles for use in influenza virus infection
MX2017008720A (en) Derivatives and methods of treating hepatitis b infections.
EP3331571A4 (en) Compositions and methods to treat viral infections
CL2015003298A1 (en) Novel bridged heteroaryl dihydropyrimidines in 6 for the treatment and prophylaxis of hepatitis B virus infection
EA201791460A1 (en) N4-HYDROXYCYTIDINE AND RELATED DERIVATIVES AND OPTIONS FOR ANTI-VIRUS APPLICATION
WO2014165128A3 (en) Hepatitis b antiviral agents
IL229165A0 (en) Aliphanes, cyclophanes, hetropanes, heterotropanes, hetero-heterotropanes, and converted thiolacenes used in the treatment of HCV infections
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
WO2012116010A3 (en) Antibiotic tolerance inhibitors
SG11201502522WA (en) 1,2,4-triazine derivatives for the treatment of viral infections.
MX2015008703A (en) miRNA-124 AS A BIOMARKER.
MX2021004464A (en) Thiazolide compounds for treating viral infections.
EP2994140A4 (en) Methods for treating hcv infection
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
MX2017000312A (en) Isoindoline derivatives for use in the treatment of a viral infection.
PH12016500465B1 (en) Deoxynojirimycin derivatives and methods of their using
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
IN2014MU00916A (en)
WO2015086738A3 (en) Hiv vaccine
EA201500942A1 (en) ANTI-VIRUS INDOLO [2,3-b] HINOXALINE
WO2015051268A3 (en) Hiv protease inhibitors against picornavirus infection
WO2015073788A3 (en) Methods and compositions for the treatment of hcmv

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14851036

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14851036

Country of ref document: EP

Kind code of ref document: A2